Lupin Acquires Specialty Product Portfolio in Germany
Mumbai, July 24, 2015:
Pharma Major Lupin Limited (Lupin) today announced that it has entered into a strategic
asset purchase agreement with TEMMLER PHARMA GMBH & CO. KG (Temmler), a part of the Aenova Group,
one of the world's largest pharmaceutical contract manufacturers, to acquire Temmler's specialty product
portfolio subject to certain closing conditions.
Based in Marburg (Germany), Temmler has a fast growing specialty portfolio of 13 products including key
Central Nervous System (CNS) products and specialty products that address rare disease areas like Myasthenia
Gravis, Huntington disease as well as fast-growing dermatology products for anti-wart treatment. Since
Huntington disease has many symptoms ranging from motoric symptoms to personality changes, both Temmler
and Hormosan products can be used to treat the disease.
Commenting on the acquisition, Ms. Vinita Gupta, Chief Executive Officer of Lupin Limited said, "We are very
pleased to add to our specialty business with this acquisition. Temmler's business has a strong strategic fit with
Lupin's Hormosan business in Germany and enables Lupin to bring an enhanced specialty CNS portfolio to the
German market. "
Dr. Maurice Chagnaud, President - Europe and Head of Inhalation Strategy, commented, "Temmler is a
profitable pharmaceutical player backed by a strong and experienced management team that is also taken on
and which will strongly support our future growth plans. Temmler operates in niche segments and its specialty
product portfolio has strong synergies with Hormosan's existing CNS portfolio. The acquisition not only
complements but would also enhance Hormosan's specialty portfolio and enables it to grow into niche therapy
Mr. Frank Elsen, Aenova Group CFO commented, “I believe that Lupin is perfectly poised to take Temmler's
product portfolio and its growth forward. We are extremely optimistic about this strategic agreement which
allows us to concentrate on our core business. As a leading CDMO we are proud to continue to manufacture and
supply at highest quality all related products to our partner Lupin."
About Lupin Limited
Headquartered in Mumbai, Lupin is an innovation led transnational pharmaceutical company producing and
developing a wide range of branded & generic formulations, APIs and biotechnology products. The Company is a
significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space
and holds global leadership positions in the Anti-TB and Cephalosporin segment.
Lupin is the 5th largest and fastest growing generics player in the US (5.3% market share by prescriptions, IMS
Health) and the 3rd largest Indian pharmaceutical company by sales. The Company is also the fastest growing top
10 generic pharmaceutical players in Japan and South Africa (IMS).
For the financial year ended 31st March 2015, Lupin's Consolidated turnover and Profit after Tax were
125,997 million (USD 2.06 billion) and 24,032 million (USD 393 million) respectively. Please visit
http://www.lupin.com for more information.
About Aenova Group
The Aenova Group is one of the world's largest providers of services covering the entire value chain for the
development and production of all the main dosage forms and product groups in the field of medicines and
dietary supplements. As the European business-to-business market leader, the Aenova Group focuses on high
standards of quality, innovative technologies and a clear vision for the future. The group operates overall 29
locations in eleven countries and employs more than 4700 people.